Patients on GLP-1RAs are considered at-risk, meaning they also should: Follow more frequent reexamination intervals Receive individualized risk counseling regarding ocular risks Get collaborative care with providers managing their diabetes and other systemic conditions Doctors of optometry have to be aware, Dr
Some studies, though not conclusive, predict that tirzepatide may in fact be more potent than GLP-1 RAs at reducing weight
References World health organization [Home page in Internet] Newsroom/Fact sheets/Detail/Obesity and overweight
doi:10.3389/fendo.2018.00058 207
On April 29, 2025, a press release hailed the Novo Nordisk tie-up for "affordable access" to semaglutide, calling it "high-quality" and "personalized." Dudum said it tackled shortages while "prioritizing safety." The Q1 earnings call echoed this, with Dudum bragging about "innovative partnerships" for consumer choice
Establishing a WeChat connection signals that you are a serious, recurring customer rather than a one-time browser
